HSBC Holdings
CCCC icon

HSBC Holdings’s C4 Therapeutics CCCC Stock Holding History

HSBC Holdings’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36K Hold
13,629
– – ﹤0.01% 2830
2025
Q4 		$26.2K Hold
13,629
– – ﹤0.01% 2893
2025
Q3 		$30.1K Sell
13,629
-11,528
-46% -$27.7K ﹤0.01% 2665
2025
Q2 		$35.6K Sell
25,157
-330
-1% -$480 ﹤0.01% 2956
2025
Q1 		$41.3K Buy
25,487
+6,128
+32% +$18.3K ﹤0.01% 2927
2024
Q4 		$68.3K Sell
19,359
-1,809
-9% -$8.99K ﹤0.01% 2952
2024
Q3 		$123K Buy
+21,168
New +$127K ﹤0.01% 2760
2024
Q1 		– Sell
-30,200
Closed -$171K – 3069
2023
Q4 		$171K Sell
30,200
-2,453
-8% -$5.59K ﹤0.01% 2510
2023
Q3 		$62K Hold
32,653
– – ﹤0.01% 2606
2023
Q2 		$90.3K Buy
32,653
+13,893
+74% +$44.7K ﹤0.01% 2444
2023
Q1 		$60.1K Buy
18,760
+8,605
+85% +$50.7K ﹤0.01% 2553
2022
Q4 		$58.9K Buy
+10,155
New +$84.2K ﹤0.01% 2954
2022
Q2 		– Sell
-10,275
Closed -$251K – 3261
2022
Q1 		$251K Buy
+10,275
New +$250K ﹤0.01% 2870

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HSBC Holdings's CCCC Position: Q1 2026 in Review

HSBC Holdings held its C4 Therapeutics (CCCC) position steady in Q1 2026 at 13,629 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #2830.

HSBC Holdings first reported a position in CCCC in Q1 2022 and has held it in 13 quarters since. The position peaked at $251K in Q1 2022. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • HSBC Holdings held 13,629 shares of C4 Therapeutics worth $36K as of Q1 2026.
  • HSBC Holdings left its C4 Therapeutics share count unchanged in Q1 2026.
  • C4 Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2830 holding.
  • HSBC Holdings first reported a position in C4 Therapeutics in Q1 2022 and has held it in 13 quarters since.
  • HSBC Holdings's C4 Therapeutics position peaked at $251K in Q1 2022.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.